Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
OBJECTIVE
This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH).


METHODS
102 children with attention-deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH-IR to OROS-MPH.


RESULTS
There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH-IR to OROS-MPH. A positive correlation was observed between the improvement in parent/caregiver-rated IOWA Conners total score (Delta IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver-rated IOWA Conners scale total scores were significant predictors of change in commission error (beta = 0.3, p = 0.005, CI = 0.4-2.3, adjusted R(2) = 0.12) and RT variability (beta = 0.3, p = 0.004, CI = 0.5-2.4, adjusted R(2) = 0.09) of visual CPT.


CONCLUSIONS
These data suggest that MPH-IR may be successfully switched to OROS-MPH treatment with associated improvements in neurocognitive performance. Large-scale controlled trials are needed to replicate these findings.
Kim
Yeni
Y
Department of Psychiatry, Division of Child and Adolescent Psychiatry, Institute of Human Behavioral Medicine, Seoul National University Hospital, Seoul, Korea.
Shin
Min-Sup
MS
Kim
Jae-Won
JW
Yoo
Hee-Jung
HJ
Cho
Soo-Churl
SC
Kim
Boong-Nyun
BN
D000284:Administration, Oral; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002648:Child; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage*; D009483:Neuropsychological Tests; D011930:Reaction Time / Q000187:drug effects
D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D008774:Methylphenidate